Oncobiomix Inc. — SEC Form D Filing

Oncobiomix Inc. filed an SEC Form D on September 16, 2026, reporting $100K raised in Health & Wellness.

Form D filing details

Filing
SEC Form D
Filing date
September 16, 2026
Amount reported
$100K
Round stage
Pre-Seed
Industry
Health & Wellness
Website
https://oncobiomix.com/

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cancer patients often lack early, specialized nutrition support, and existing nutrition care methods for oncology patients typically lack direct measurement of the gut microbiome, making it difficult to understand its impact on food tolerance, symptoms, and recovery.

Solution

Oncobiomix provides microbiome-guided nutrition care by combining gut-microbiome sequencing and analysis (RebiomiX) with personalized consultations from oncology dietitians, offering a data-driven approach to nutrition plans for cancer patients.

Why now

Advances in microbiome research and sequencing technology now allow for a deeper understanding of the gut's role in health and disease, enabling personalized nutritional interventions for cancer patients where generic advice often falls short.

Verdict

This cleared because the small raise reflected a strong belief in the intersection of personalized nutrition and oncology, betting that a niche service for a high-need population could validate initial product-market fit. Investors implicitly bet on the convergence of established microbiome science with an underserved cancer patient segment. This cleared as an exploratory bet on a specific application, not as a scalable, novel biotech platform. Limited upside stemmed from the highly specialized, potentially direct-to-consumer (DTC) nature of the offering, which often struggles with acquisition costs and reimbursement.

Source: SEC EDGAR Form D filing